Xeris Biopharma Holdings is a company that has successfully launched products which are already generating revenue. Read why ...

The trial evaluates the safety and efficacy of Eyecyte-RPE in patients with geographic atrophy secondary to dry age-related ...

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on ...

Specialist Consultant Paediatrician and Honorary Senior Fellow, Postgraduate Institute of Medicine, University of Colombo, ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...

KANSAS CITY, Mo., June 17, 2025 /PRNewswire/ — NextStage Clinical Research is proud to announce the opening of its newest ...

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free ...

A breakthrough in breast cancer research is showing promising signs in the development of a vaccine for the disease. Anixa Biosciences, Inc. is working with the Cleveland Clinic to ...

The investigational treatment DZD8586 elicited encouraging antitumor activity with manageable toxicity in heavily pretreated ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.